SCM
SUPN icon

Segantii Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Segantii Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,300
Closed -$41K – 233
2017
Q1 		$41K Buy
+1,300
New +$34.8K 0.01% 304

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RCAMU
Rothschild & Co Asset Management US Stamford, Connecticut $6.58B AUM 4.5% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return

Segantii Capital Management's SUPN Position: Q2 2017 in Review

Segantii Capital Management sold out of Supernus Pharmaceuticals (SUPN) in Q2 2017, closing a stake of 1,300 shares — an estimated $41K sold.

Segantii Capital Management first reported a position in SUPN in Q1 2017 and held it in 1 quarter. The position peaked at $41K in Q1 2017. 265 funds tracked by Wall St. Rank hold SUPN as of Q2 2017.

  • Segantii Capital Management reported no remaining Supernus Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Segantii Capital Management sold 1,300 Supernus Pharmaceuticals shares in Q2 2017, an estimated $41K.
  • Segantii Capital Management first reported a position in Supernus Pharmaceuticals in Q1 2017 and held it in 1 quarter.
  • Segantii Capital Management's Supernus Pharmaceuticals position peaked at $41K in Q1 2017.
  • 265 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2017.

Based on Segantii Capital Management's 13F filing for Q2 2017, filed 2 Aug 2017.